公开(公告)号：US12128018B2

公开(公告)日：2024-10-29

申请号：US16246320

申请日：2019-01-11

Applicant: KDAc Therapeutics, Inc.

Inventor： Edward Holson ,  Mariana Nacht

IPC: A01N43/00 ,  A01N43/46 ,  A61K31/167 ,  A61K31/403 ,  A61K31/415 ,  A61K31/55 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  A61K39/00

CPC classification number: A61K31/167 ,  A61K31/403 ,  A61K31/415 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/545 ,  C07K2317/73 ,  A61K31/167 ,  A61K2300/00 ,  A61K31/403 ,  A61K2300/00 ,  A61K31/415 ,  A61K2300/00 ,  A61K39/3955 ,  A61K2300/00

Abstract: Aspects of the disclosure relate to compositions, kits, and methods for the treatment of cancer that utilize a selective histone deacetylase 3 (HDAC3) inhibitor. In some aspects, the compositions, kits, and methods relate to use of a selective HDAC3 inhibitor in combination with an immunotherapy agent (e.g., an immune checkpoint inhibitor).

公开(公告)号：US20240327334A1

公开(公告)日：2024-10-03

申请号：US18390287

申请日：2023-12-20

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Xuri GAO ,  Bin WANG ,  Hui CAO ,  Jiajun ZHANG ,  Yuk Ming SIU ,  Jiang LONG ,  Wei LI ,  Matthew C. RHODES ,  Xuechao XING ,  Jianming YU ,  Scott MITCHELL ,  Yat Sun OR

IPC: C07C233/56 ,  A61K31/166 ,  A61K31/277 ,  A61K31/337 ,  A61K31/365 ,  A61K31/381 ,  A61K31/397 ,  A61K31/40 ,  A61K31/403 ,  A61K31/415 ,  A61K31/4152 ,  A61K31/416 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4402 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/506 ,  A61K31/535 ,  A61K31/662 ,  A61P31/14 ,  C07C243/30 ,  C07C255/46 ,  C07C255/66 ,  C07D205/04 ,  C07D207/16 ,  C07D209/52 ,  C07D209/56 ,  C07D213/40 ,  C07D215/12 ,  C07D231/08 ,  C07D231/12 ,  C07D231/56 ,  C07D239/26 ,  C07D241/12 ,  C07D249/06 ,  C07D263/32 ,  C07D263/34 ,  C07D265/02 ,  C07D277/28 ,  C07D295/185 ,  C07D305/08 ,  C07D307/58 ,  C07D333/20 ,  C07D333/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/40

CPC classification number: C07C233/56 ,  A61K31/166 ,  A61K31/277 ,  A61K31/337 ,  A61K31/365 ,  A61K31/381 ,  A61K31/397 ,  A61K31/40 ,  A61K31/403 ,  A61K31/415 ,  A61K31/4152 ,  A61K31/416 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4402 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/506 ,  A61K31/535 ,  A61K31/662 ,  A61P31/14 ,  C07C243/30 ,  C07C255/46 ,  C07C255/66 ,  C07D205/04 ,  C07D207/16 ,  C07D209/52 ,  C07D209/56 ,  C07D213/40 ,  C07D215/12 ,  C07D231/08 ,  C07D231/12 ,  C07D231/56 ,  C07D239/26 ,  C07D241/12 ,  C07D249/06 ,  C07D263/32 ,  C07D263/34 ,  C07D265/02 ,  C07D277/28 ,  C07D295/185 ,  C07D305/08 ,  C07D307/58 ,  C07D333/20 ,  C07D333/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/4015

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240315956A1

公开(公告)日：2024-09-26

申请号：US18574757

申请日：2022-07-08

Applicant: US NANO FOOD & DRUG INC

Inventor： Hing Sang PUI ,  Yip Ching PUI ,  Yip Shu PUI

IPC: A61K9/46 ,  A61K9/00 ,  A61K31/194 ,  A61K31/4015 ,  A61K31/415 ,  A61K47/12 ,  A61K47/32 ,  A61K47/38

CPC classification number: A61K9/0007 ,  A61K9/0095 ,  A61K31/194 ,  A61K31/4015 ,  A61K31/415 ,  A61K47/12 ,  A61K47/32 ,  A61K47/38

Abstract: The disclosure is directed to the method of production of the composition of a cyclooxygenase-2 (COX-2) inhibitor comprising a water soluble excipient comprising HPMC, an organic acid and one or more other components. The composition may be in the form of pellets, a tablet, a capsule or granules with higher dissolution of the API or fast disintegration in the aqueous medium. In some embodiments, the composition further contains a carbonate salt to form a weakly effervescent disintegration formulation.

公开(公告)号：US12097185B2

公开(公告)日：2024-09-24

申请号：US18047289

申请日：2022-10-18

Applicant: Neurosense Therapeutics Ltd.

Inventor： Alon Ben Noon ,  Jeffrey Sterling ,  Oron Yacoby-Zeevi ,  Sharon Cohen Vered

IPC: A61K31/415 ,  A61K9/20 ,  A61K31/496

CPC classification number: A61K31/415 ,  A61K9/2054 ,  A61K31/496

Abstract: Embodiments relate to a tablet comprising celecoxib and ciprofloxacin or a pharmaceutically acceptable salt thereof, and low viscosity hydroxypropyl methylcellulose having a viscosity of less than 150 cP, when measured as a 2% solution in water at 20° C.

公开(公告)号：US20240299544A1

公开(公告)日：2024-09-12

申请号：US18569178

申请日：2022-06-16

Applicant: Health Research, Inc. ,  H. Lee Moffitt Cancer Center and Research Institute, Inc.

Inventor： Pawel KALINSKI ,  Brian CZERNIECKI

IPC: A61K39/00 ,  A61K31/415 ,  A61K31/713 ,  C07K16/28 ,  C12N5/0784

CPC classification number: A61K39/4615 ,  A61K31/415 ,  A61K31/713 ,  A61K39/4622 ,  A61K39/464406 ,  C07K16/2827 ,  C12N5/0639 ,  A61K2039/505 ,  C12N2501/056 ,  C12N2501/2301 ,  C12N2501/24 ,  C12N2501/25

Abstract: Provided are compositions and methods for prophylaxis or therapy of cancer. The compositions comprise α-type-1 dendritic cells that have been treated with intact proteins that comprise cancer antigens, or peptides that comprise cancer antigens, or combinations thereof. The approaches can also include adding a chemokine-modulating regimen.

公开(公告)号：US20240294493A1

公开(公告)日：2024-09-05

申请号：US18650059

申请日：2024-04-29

Applicant: Emory University

Inventor： Dennis Liotta ,  Stephen Traynelis ,  Yao Jing

IPC: C07D401/04 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4709 ,  A61K31/497 ,  A61K45/06 ,  A61P25/00 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  C07D231/06 ,  C07D401/14 ,  C07D405/04 ,  C07D409/04 ,  C07D409/14

CPC classification number: C07D401/04 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4709 ,  A61K31/497 ,  A61P25/00 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  C07D231/06 ,  C07D405/04 ,  C07D409/04 ,  C07D409/14 ,  A61K45/06 ,  C07D401/14

Abstract: A compound according to Formula (I) or salts or prodrugs thereof and pharmaceutical formulations comprising the compound are provided herein for the treatment of neurological disorders. The disorders may include providing neuroprotection, preventing neurodegeneration, treating neuropathic pain or treating schizophrenia, psychoses or depression. Furthermore, the compounds may be used in combination with another active ingredient.

公开(公告)号：US20240277701A1

公开(公告)日：2024-08-22

申请号：US18368709

申请日：2023-09-15

Applicant: Agios Pharmaceuticals, Inc.

Inventor： Shin-San Michael Su ,  Lenny Dang

IPC: A61K31/496 ,  A61K31/415 ,  A61K31/4406 ,  A61K31/47 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/535 ,  A61P7/06 ,  C07C13/04 ,  C07C307/10 ,  C07D205/04 ,  C07D213/81 ,  C07D215/14 ,  C07D235/06 ,  C07D241/04 ,  C07D241/20 ,  C07D271/12 ,  C07D295/192 ,  C07D307/14 ,  C07D333/24 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12

CPC classification number: A61K31/496 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/535 ,  A61P7/06 ,  C07C307/10 ,  C07D205/04 ,  C07D213/81 ,  C07D215/14 ,  C07D235/06 ,  C07D241/04 ,  C07D241/20 ,  C07D271/12 ,  C07D295/192 ,  C07D333/24 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12 ,  A61K31/415 ,  A61K31/4406 ,  A61K31/47 ,  C07C13/04 ,  C07D307/14

Abstract: Described herein are methods for using compounds that activate pyruvate kinase.

公开(公告)号：US20240252458A1

公开(公告)日：2024-08-01

申请号：US18403027

申请日：2024-01-03

Applicant: The Rockefeller University

Inventor： Sohail F. Tavazoie ,  Nora Pencheva

IPC: A61K31/195 ,  A61K31/136 ,  A61K31/18 ,  A61K31/265 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/416 ,  A61K31/4164 ,  A61K31/4174 ,  A61K31/47 ,  A61K31/5377 ,  A61K31/675 ,  A61K38/17 ,  A61K45/06 ,  C07C217/54 ,  C07D233/64 ,  C07F9/6506 ,  C12Q1/6886 ,  G01N33/574

CPC classification number: A61K31/195 ,  A61K31/136 ,  A61K31/18 ,  A61K31/265 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/416 ,  A61K31/4164 ,  A61K31/4174 ,  A61K31/47 ,  A61K31/5377 ,  A61K31/675 ,  A61K38/1709 ,  A61K38/177 ,  A61K45/06 ,  C07C217/54 ,  C07D233/64 ,  C07F9/6506 ,  C12Q1/6886 ,  G01N33/5743 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N2500/10

Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.

公开(公告)号：US20240245685A1

公开(公告)日：2024-07-25

申请号：US18436072

申请日：2024-02-08

Applicant: VK Research Associates Inc

Inventor： Siva Rama Krishna Nutalapati ,  Victor Chehebar

IPC: A61K31/519 ,  A61K9/00 ,  A61K9/20 ,  A61K9/24 ,  A61K9/48 ,  A61K31/135 ,  A61K31/138 ,  A61K31/167 ,  A61K31/192 ,  A61K31/195 ,  A61K31/407 ,  A61K31/415 ,  A61K31/4439 ,  A61K31/4985 ,  A61K31/616 ,  A61K31/80 ,  A61K33/00 ,  A61K33/10 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36

CPC classification number: A61K31/519 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2068 ,  A61K9/209 ,  A61K9/2095 ,  A61K9/4808 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/135 ,  A61K31/138 ,  A61K31/167 ,  A61K31/192 ,  A61K31/195 ,  A61K31/407 ,  A61K31/415 ,  A61K31/4439 ,  A61K31/4985 ,  A61K31/616 ,  A61K31/80 ,  A61K33/00 ,  A61K33/10 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36

Abstract: Combination oral formulations comprising a phosphodiesterase-5 inhibitor and an additional active agent that can reduce or eliminate a side effect associated with phosphodiesterase-5 inhibitor therapy are described. Methods of treatment using the combinations and kit formulations are included.

公开(公告)号：US20240238330A1

公开(公告)日：2024-07-18

申请号：US18419108

申请日：2024-01-22

Applicant: Proteobioactives Pty Ltd

Inventor： Peter Ghosh ,  Jack Edelman

IPC: A61K31/737 ,  A61K9/00 ,  A61K9/48 ,  A61K31/196 ,  A61K31/365 ,  A61K31/415 ,  A61K31/42 ,  A61K31/444 ,  A61P19/02 ,  A61P29/00

CPC classification number: A61K31/737 ,  A61K9/0053 ,  A61K9/4816 ,  A61K31/196 ,  A61K31/365 ,  A61K31/415 ,  A61K31/42 ,  A61K31/444 ,  A61P19/02 ,  A61P29/00

Abstract: Pharmaceutical and veterinary compositions for oral administration comprising a therapeutically effective amount of at least one coxib together with a therapeutically effective amount of pentosan polysulfate or a pharmaceutically acceptable salt thereof are described. The compositions have application for the prophylaxis or treatment of pain and/or inflammation. There is also described a pharmaceutical or vete1inal) composition comprising a therapeutically effective amount of at least one coxib. The compositions in at least some forms may be lactose free and/or provided in a non-gelatin capsule. Further, there are provided methods for administration of a therapeutically effective amount of at least one coxib in combination with pentosan polysulfate or a pharmaceutically acceptable salt thereof for the prophylaxis or treatment of pain and/or inflammation.